Menu Search
Equities

CogState Ltd

CGS:ASX

CogState Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.96
  • Today's Change-0.015 / -1.54%
  • Shares traded8.95k
  • 1 Year change-38.26%
  • Beta0.7089
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year CogState Ltd grew revenues 7.36% from 40.45m to 43.43m while net income improved 52.75% from 3.57m to 5.45m.
Gross margin55.96%
Net profit margin12.55%
Operating margin16.35%
Return on assets9.74%
Return on equity13.87%
Return on investment12.51%
More ▼

Cash flow in USDView more

In 2024, CogState Ltd increased its cash reserves by 5.05%, or 1.45m. The company earned 5.78m from its operations for a Cash Flow Margin of 13.32%. In addition the company used 1.12m on investing activities and also paid 3.22m in financing cash flows.
Cash flow per share0.07
Price/Cash flow per share13.90
Book value per share0.3543
Tangible book value per share0.2636
More ▼

Balance sheet in USDView more

CogState Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 30.12m.
Current ratio3.45
Quick ratio--
Total debt/total equity0.0164
Total debt/total capital0.0162
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.